PRL and systemic lupus erythematosus: Treatment with bromocriptine, a dopamine receptor agonist that selectively inhibits prolactin secretion, has been demonstrated to effectively suppress the disease in NZB/NZW (B/W) F1 mice, (a SLE-like animal model), where lower anti-DNA antibodies and circulating IgG levels were observed, as well as a longer lifespan [115].